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ABSTRACT
Introduction Pre- diabetes, a status conferring high risk 
of overt diabetes, is defined differently by the American 
Diabetes Association (ADA) and the WHO. We investigated 
the impact of applying definitions of pre- diabetes on 
lifetime risk of diabetes in women and men from the 
general population.
Research design and methods We used data from 8844 
women without diabetes and men aged ≥45 years from 
the prospective population- based Rotterdam Study in the 
Netherlands. In both gender groups, we calculated pre- 
diabetes prevalence according to ADA and WHO criteria 
and estimated the 10- year and lifetime risk to progress to 
overt diabetes with adjustment for competing risk of death.
Results Out of 8844 individuals, pre- diabetes was identified 
in 3492 individuals (prevalence 40%, 95% CI 38% to 41%) 
according to ADA and 1382 individuals (prevalence 16%, 
95% CI 15% to 16%) according to WHO criteria. In both 
women and men and each age category, ADA prevalence 
estimates doubled WHO- defined pre- diabetes. For women 
and men aged 45 years having ADA- defined pre- diabetes, the 
10- year risk of diabetes was 14.2% (95% CI 6.0% to 22.5%) 
and 9.2% (95% CI 3.4% to 15.0%) compared with 23.2% 
(95% CI 6.8% to 39.6%) and 24.6% (95% CI 8.4% to 40.8%) 
in women and men with WHO- defined pre- diabetes. At age 45 
years, the remaining lifetime risk to progress to overt diabetes 
was 57.5% (95% CI 51.8% to 63.2%) vs 80.2% (95% CI 
74.1% to 86.3%) in women and 46.1% (95% CI 40.8% to 
51.4%) vs 68.4% (95% CI 58.3% to 78.5%) in men with pre- 
diabetes according to ADA and WHO definitions, respectively.
Conclusion Prevalence of pre- diabetes differed 
considerably in both women and men when applying 
ADA and WHO pre- diabetes definitions. Women with pre- 
diabetes had higher lifetime risk to progress to diabetes. 
The lifetime risk of diabetes was lower in women and 
men with ADA- defined pre- diabetes as compared with 
WHO. Improvement of pre- diabetes definition considering 
appropriate sex- specific and age- specific glycemic 
thresholds may lead to better identification of individuals at 
high risk of diabetes.
INTRODUCTION
The worldwide prevalence of diabetes varies 
between 8.8% and 14.2% and is expected to 
increase in coming years.1–3 Although gender 
differences exist in the prevalence of obesity 
and diabetes,1 4 lifestyle and pharmacological 
interventions are the cornerstone to deflect 
the global rise in diabetes prevalence among 
both women and men.5–8 Pre- diabetes, a condi-
tion with elevated blood glucose levels below 
the threshold of diabetes, places women and 
Significance of this study
What is already known about this subject?
 ► Pre- diabetes is a highly prevalent condition and 
increases the risk for women and men to develop 
diabetes.
 ► Data on the impact of applying different definitions 
of pre- diabetes in women and men and lifetime risk 
to eventually progress to diabetes are scarce.
What are the new findings?
 ► Women with pre- diabetes have significantly higher 
lifetime risk to progress to diabetes than men.
 ► The American Diabetes Association (ADA) criteria 
diagnose up to half the women and men as pre- 
diabetes, more than twice the prevalence of WHO- 
defined pre- diabetes. Furthermore, the lifetime risk 
to progress to diabetes is substantially lower in 
women and men with ADA- defined pre- diabetes as 
compared with the WHO- defined pre- diabetes.
How might these results change the focus of 
research or clinical practice?
 ► Our findings indicate the need for setting appropriate 
population- wide sex- specific and age- specific gly-
cemic thresholds for pre- diabetes.
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men at high risk of diabetes.9–11 The American Diabetes 
Association (ADA) and the WHO are the authorities that 
publish the major clinical guidelines for pre- diabetes 
definition.12 13 The main difference in the definition 
of pre- diabetes between the ADA and WHO is differ-
ence in the threshold of the glycemic index. For fasting 
glucose, the threshold according to the ADA guideline 
is 5.6 mmol/L, whereas the WHO defines a threshold 
of 6.0 mmol/L. To be clinically useful in prevention, 
pre- diabetes definition should accurately identify future 
cases of diabetes. Recent evidence points towards gender 
differences in epidemiology of both diabetes and obesity, 
possibly resulting from biological and lifestyle factors but 
also from disparities in treatment and prevention.1 4 14 
For example, more men are overweight at a younger age 
and women develop diabetes at a higher body mass index 
(BMI) then men. Gender differences also exist in the 
development of diabetes- associated complications, such 
as coronary heart disease and stroke.15 16 These findings 
highlight the importance of a sex- specific approach in 
the assessment of high- risk individuals for diabetes. In 
preventive settings, long- term absolute risks are pref-
erable by clinicians and patients over relative risks for 
risk communication and estimation.17–19 Lifetime risks 
provide straightforward messages to patients and clini-
cians on cumulative risks of developing certain diseases 
during a life span.11 20 Data on the lifetime risk of devel-
oping diabetes in women and men for different defini-
tions of pre- diabetes have been lacking or are limited to 
absolute risks within a limited time period.21
Hence, our aim was to study the impact of applying 
ADA and WHO pre- diabetes definitions on women and 
men from a community- dwelling population and to assess 
their prediction of lifetime risk to progress to diabetes. 
We first studied the proportion that meets the diagnosis 
of pre- diabetes according to the ADA and WHO criteria. 
Second, we examined the remaining 10- year and lifetime 
risk for women and men to progress to overt diabetes 
across different age groups according to both criteria. We 
then compared the lifetime risk of developing diabetes 
between WHO- diagnosed and ADA- diagnosed pre- 
diabetes status in both women and men.
RESEARCH DESIGN AND METHODS
Study population
We used data from the Rotterdam Study, a prospective 
community- dwelling study in a district of Rotterdam, the 
Netherlands. The Rotterdam Study has been described 
in detail elsewhere.22 In 1990, 7983 individuals aged 55 
years and older were included in the first cohort of the 
Rotterdam Study. In 2000, the study was extended with a 
second cohort of 3011 individuals who had reached the 
age of 55 years or had moved into the research area since 
the beginning of the first cohort. Further, in 2006, a third 
cohort was started, including 3932 individuals of 45 years 
and older. For the current analyses, we used data from 
the third center visit of the first cohort (1997–1999) and 
the first center visit of the second and third cohorts as 
baseline. We excluded 1376 participants without avail-
able fasting glucose measurement and 314 from whom 
informed consent was not obtained. Then we excluded 
1206 participants with diabetes. This led to inclusion of 
8844 individuals 45 years and older who were free from 
diabetes at baseline for this study (flowchart in figure 1). 
We included individuals with pre- diabetes (n=3492) to 
calculate the lifetime risk of diabetes.
Assesment of glycemic status at baseline and follow-up
All participants were subject to an overnight fasting period 
after which blood was drawn at the research facility. All 
biochemical variables, including glucose, were assessed 
using fasting serum. Glucose and other biochemical 
variables were measured using a COBAS 8000 Modular 
Analyzer (Roche Diagnostics). The corresponding inter-
assay coefficient of variation of glucose was <1.4%. Indi-
viduals were categorized at baseline according to glycemic 
state using the WHO and ADA guidelines. For the WHO, 
individuals with fasting blood glucose levels of 6.0 mmol/L 
or lower were included in the group of normoglycemic indi-
viduals. Individuals with fasting glucose levels of >6.0 and 
<7.0 mmol/L were diagnosed with pre- diabetes. For the 
categorization of individuals according to the ADA guide-
lines, a fasting glucose of ≥5.6 and <7.0 mmol/L were cate-
gorized as pre- diabetes. Individuals in the normoglycemic 
and pre- diabetes group did not use any antidiabetic medi-
cation. From baseline assessment throughout follow- up, 
individuals were analyzed according to their category of 
pre- diabetes at baseline (WHO or ADA). Incident type 2 
diabetes was diagnosed based on data from general prac-
titioners, hospital discharge letters, regular research center 
visits and pharmacy records as a fasting blood glucose level 
of ≥7.0 and non- fasting glucose levels of ≥11.0 (when fasting 
samples were unavailable) and/or the use of blood glucose- 
lowering medication. Pharmacy data covered more than 
95% of the cohort study population.23 Each incident event 
of type 2 diabetes mellitus was coded by two independent 
medical doctors. In case of disagreement, consensus was 
sought in a meeting with an endocrinologist. Follow- up 
data were completed until 1 January 2012. Completeness of 
follow- up until 1 January 2012 was 99.3%.
Assessment of all-cause mortality
Follow- up on vital status of the Rotterdam Study partici-
pants was obtained from the medical records of general 
practitioners and municipal records and were completed 
until 1 January 2012.
Statistical analysis
Baseline characteristics were compared between women 
and men using an independent sample t- test and χ² 
for variables with a normal distribution. Comparisons 
between groups for continuous variables that were 
not normally distributed were performed with Mann- 
Whitney U tests. Prevalence of pre- diabetes according to 
the ADA and WHO diagnostic criteria was calculated for 
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five age categories, in women and men separately: 45–55, 
55–65, 65–75, 75–85, and 85 years and older. In these age 
categories, an age of exactly 55 years fell into age cate-
gory 55–65 years, and every age below 55 years until age 
45 years fell into age category 45–55 years, and so on. 
CIs for the prevalence were calculated using the  prop. 
test function in the ‘stats’ library in R. Ten- year and life-
time risk estimates for the progression to diabetes were 
calculated for individuals with pre- diabetes according to 
WHO and ADA diagnostic criteria at the index ages 45, 
55, 65, 75, and 85 years. For these calculations, a modi-
fied version of survival analysis according to Kaplan- 
Meier was used. In this modified version, death free 
from diabetes is a separate event. For each age during 
follow- up, we calculated the incidence of disease and 
death free from diabetes.
Survival probabilities, age- specific HRs, cumulative 
incidences and incidence rates are calculated in a way 
similar to that of Kaplan- Meier. In the lifetime risk calcu-
lation, the competing risk of death is taken into account 
in order to not overestimate the lifetime risk of diabetes 
when the competing risk is high (more detailed descrip-
tion in online supplemental file 1).The lifetime risk esti-
mates reflect the risk at the index age to the age of last 
observation (107 years in our study). The missing value 
rate for covariates was less than 5% and was therefore 
considered to be inconsequential. For the analysis of all 
data, IBM SPSS Statistics V.21.0.0.1 and R V.2.1 with the 
‘etm’ and ‘survival’ libraries were used.
RESULTS
Baseline characteristics of the population
The baseline characteristics of the study population are 
summarized in table 1. In a population of 8844 individ-
uals without diabetes, 3492 had pre- diabetes (prevalence 
40%, 95% CI 38% to 41%) according to the ADA criteria, 
of whom 1780 were women (51%), while 1382 individuals 
(prevalence 16%, 95% CI 15% to 16%) had pre- diabetes 
according to the WHO criteria, of whom 692 were women 
(50.1%). Women with pre- diabetes were older and had 
higher BMI and higher insulin levels compared with men.
Prevalence of pre-diabetes at different ages
As displayed in table 2, prevalence estimates of ADA pre- 
diabetes were more than twice the prevalence of WHO 
pre- diabetes in each age category in both women and men. 
Furthermore, prevalence of pre- diabetes was higher in men 
compared with women in each age category. The differ-
ence in prevalence of pre- diabetes between women and 
men was largest at younger age groups, and this gender gap 
narrowed with advancing age.
10-year risk of diabetes for ADA and WHO pre-diabetes 
diagnosis
For women and men aged 45 years with pre- diabetes 
based on the ADA criteria, the 10- year risk of diabetes was 
14.2% (95% CI 6.0% to 22.5%) and 9.2% (95% CI 3.4% 
to 15.0%) (p value for gender difference 0.16) compared 
with 23.2% (95% CI 6.8% to 39.6%) and 24.6% (95% 
Figure 1 Flowchart of the selection of study participants. ADA, American Diabetes Association.
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CI 8.4% to 40.8%) in women and men with WHO- 
defined pre- diabetes (p value for gender difference 0.45) 
(table 3). The 10- year risk of diabetes increased up to the 
age of 75 years, after which it decreased. Other than in 
age category 55–65 and 75–85 years, there were no statis-
tically significant gender differences in 10- year risks for 
diabetes in ADA and WHO pre- diabetes.
Lifetime risk for diabetes for ADA and WHO pre-diabetes 
diagnosis
During a total of 27 679 person- years of follow- up, 632 
individuals that had pre- diabetes according to ADA 
criteria at baseline developed diabetes and 709 died 
(diabetes incidence rate per 1000 person- years: 22.8, 
95% CI 21.1 to 24.7; mortality rate per 1000 person- years 
25.6, 95% CI 23.8 to 7.6; median follow- up time 8.1 years 
with a maximum follow- up time of 14.7 years). In indi-
viduals who were diagnosed with pre- diabetes according 
to WHO criteria, 425 developed diabetes and 257 died 
during 9884 person- years of follow- up (diabetes inci-
dence rate per 1000 person- years: 43.0, 95% CI 39.0 to 
47.3; mortality rate per 1000 person- years: 26.0, 95% CI 
22.9 to 29.41; median follow- up time 5.7 years with a 
maximum follow- up time of 14.7 years). In table 3, the 
remaining lifetime risks of diabetes for women and men 
Table 1 Baseline characteristics of participants by gender and prevalent pre- diabetes
Characteristics
Women Men
ADA
(n=1780)
WHO
(n=692)
Normoglycemia
(n=3323)*
ADA
(n=1712)
WHO
(n=690)
Normoglycemia
(n=2029)*
Age (years) 67.2±9.7† 67.7±9.7† 63.9±10.0 65.1±9.0 65.4±8.9 63.6±9.6
Waist circumference 
(cm)
92.8±12.2† 94.8±12.7† 87.1±11.0† 99.8±10.2 101.5±10.0 95.7±9.5
Body mass index (kg/
m2)
28.4±4.8† 29.0±5.0† 26.4±4.1† 27.4±3.4 28.1±3.6 26.2±3.3
Total cholesterol 
(mmol/L)
6.0±1.0† 5.9±1.0† 5.9±1.0† 5.6±1.0 5.6±1.0 5.5±1.0
Triglycerides (mmol/L)‡ 1.4 (1.0–1.8) 1.5 (1.0–2.0) 1.2 (0.8–1.5)† 1.4 (1.0–1.9) 1.5 (1.0–2.0) 1.3 (0.9–1.7)
Insulin (pmol/L)‡ 85 (55–115)† 95 (59–131) 62 (42–83) 79 (51–108) 91 (59–123) 64 (42–87)
Glucose (mmol/L)‡ 5.9 (5.7–6.2) 6.3 (6.1–6.5) 5.1 (4.9–5.3)† 5.9 (5.7–6.2) 6.3 (6.1–6.5) 5.2 (5.0–5.4)
Systolic blood pressure 
(mm Hg)
142±21 145±21 135±21† 143±20 146±21 137±20
Diastolic blood pressure 
(mm Hg)
78±11† 79±12† 78±11† 81±12 82±12 79±11
Hypertension, n (%) 1042 (58.5) 436 (63.0) 1420 (43.2) 981 (57.3) 437 (63.3) 878 (43.9)
Use of blood pressure- 
lowering drugs, n (%)
536 (30.1)† 239 (34.5) 579 (17.4) 414 (24.2) 198 (28.7) 316 (15.6)
Current smoking, n (%) 117 (6.6)† 45 (6.5)† 207 (6.3)† 244 (14.3) 99 (14.3) 283 (14.1)
Former smoking (n, %) 529 (29.7)† 214 (30.9)† 894 (27.2)† 885 (51.7) 339 (49.1) 1023 (50.8)
Values are mean±SD or median (IQR) for characteristics with skewed distributions.
*Fasting glucose <5.6 mmol/L.
†Statistically significant gender difference, corrected for age.
‡Only fasting samples.
ADA, American Diabetes Association.
Table 2 Prevalence of pre- diabetes according to the ADA and WHO diagnostic criteria in different age categories in women 
and men.
Age interval (years)
Women Men
ADA WHO ADA WHO
45–55 18% (15% to 21%) 6% (4% to 8%) 31% (28% to 35%) 10% (8% to 13%)
55–65 34% (32% to 36%) 13% (12% to 15%) 48% (46% to 51%) 20% (18% to 22%)
65–75 38% (36% to 41%) 15% (13% to 17%) 49% (46% to 52%) 19% (17% to 21%)
75–85 45% (41% to 48%) 18% (16% to 21%) 48% (43% to 52%) 22% (18% to 26%)
85 and older 46% (38% to 54%) 20% (14% to 27%) 53% (40% to 65%) 17% (9% to 28%)
ADA, American Diabetes Association.
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with pre- diabetes according to ADA and WHO diagnostic 
criteria are summarized. At age 45 years, the remaining 
lifetime risk to progress to overt diabetes among individ-
uals with ADA- defined pre- diabetes was 57.5% (95% CI 
51.8% to 63.2%) for women and 46.1% (95% CI 40.8% 
to 51.4%) for men. The lifetime and 10- year risk for indi-
viduals with normoglycemia and glucose levels between 
5.6 and 6.1 were lower (online supplemental table 1). 
The remaining lifetime risks attenuated with increasing 
index age. In figure 2, the cumulative incidence of type 2 
diabetes is displayed for two categories of fasting glucose 
levels in individuals aged 45 years and adjusted for the 
competing risk of death.
CONCLUSION
In this population- based cohort study, we found that ADA 
criteria for pre- diabetes assigned up to half of women 
and men as pre- diabetes, more than twice the prevalence 
estimates of pre- diabetes generated by WHO criteria in 
both genders for each age category. Approximately half 
the individuals diagnosed with pre- diabetes according to 
ADA- definition and approximately two- thirds of WHO- 
defined pre- diabetes at age 45 years would eventually 
develop diabetes in their remaining life span. Further-
more, women with pre- diabetes at age 45 years had 
higher lifetime risk to progress to diabetes than men.
In this study, we are the first to compare lifetime 
diabetes risk estimates between women and men for 
ADA and WHO pre- diabetes criteria. The lifetime risk 
of women with pre- diabetes to progress to diabetes was 
higher than that of men with pre- diabetes in most age 
categories. This could be an effect of susceptibility as 
men are more likely to develop diabetes at a younger 
age and lower BMI compared with women,4 24 25 which 
indicates them being more vulnerable to the effects of 
obesity and ageing compared with their female counter-
parts.26 Therefore, more men than women could already 
have had diabetes before the start of follow- up, making 
women at risk of developing diabetes during the course 
of follow- up. We have previously provided evidence for 
this observation.11 Also, women had higher BMI at base-
line, which is an established risk factor for type 2 diabetes. 
Pre- diabetes according to ADA criteria was highly preva-
lent in our study population, and pre- diabetes was more 
prevalent in men than in women. US data from 2011 
to 2012 in the age category of 45–64 years show that 
pre- diabetes prevalence based on any of three glucose 
dysregulation criteria (glycated hemoglobin (HbA1c), 
fasting plasma glucose and 2- hour plasma glucose level) 
was 44.9%.27 Since their prevalence was based on three 
glycemic criteria, the slightly higher US prevalence could 
be comparable or lower compared with our prevalence 
estimate based on fasting plasma glucose solely. In our 
study, the prevalence of pre- diabetes was higher than that 
in a UK population (35.3% in 2011).28 However, the UK 
study diagnosis was less sensitive29 due to a sole HbA1c 
measurement and participants were younger. Similar to 
our study, pre- diabetes had trends of higher prevalence 
in men compared with women. As previously described, 
men may thus be more vulnerable to the metabolic 
effects of obesity.25 The gap in prevalence of pre- diabetes 
between men and women narrowed with ageing. This 
could be due to the fact that more men are overweight at 
younger ages and men are likely to develop diabetes type 
2 at a younger age and at a lower BMI than women.4 24 
Women tend to become more overweight than men and 
generally do after the age of 45 years.30 Another explana-
tion could be that impaired fasting glucose (IFG) is more 
prevalent in men compared with women, in whom more 
often impaired glucose tolerance (IGT) is observed.31
We assessed pre- diabetes as a homogeneous entity 
using IFG, without analyzing IGT separately or combined 
(IFG–IGT). Of note, IFG and IGT have different patho-
physiological underlying mechanisms Furthermore, IFG 
is more prevalent in men, whereas IGT is more likely 
to be identified in women.31 IFG and IGT overlap in 
Figure 2 Lifetime risk of type 2 diabetes at 45 years of age, 
adjusted for the competing risk of death, in women and men. 
The functions represent the cumulative incidences of type 2 
diabetes for individuals aged 45 who have fasting glucose 
values between 6.0 and 7.0 mmol/L (WHO, red) and between 
5.6 and 7.0 mmol/L (ADA, green). ADA, American Diabetes 
Association.
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20%–30% of pre- diabetes,32 and the combination of IFG 
and IGT best predicts incident type 2 diabetes. There-
fore, the lifetime risks of the pre- diabetes estimated in 
our study might be subject to a certain level of underes-
timation of true lifetime risk of diabetes. Nevertheless, 
we have a large prospective population- based study with 
long follow- up. Given the time- consuming nature of the 
IGT testing with potential loss- to- follow- up with poor 
reproducibility33 rendering missing data, we have chosen 
a straightforward approach with fasting glucose measure-
ments. Other aspects of single glucose measurements 
are that, although we had complete data on fasting state 
of the participant and procedures were standardized, 
unforeseen preanalytical conditions could interfere with 
the single diagnostic glucose measurement. Further-
more, an extensive amount of information is lost through 
dichotomizing fasting glucose into a diseased or non- 
diseased state. This is, however, inevitable from a clinical 
diagnostic and therapeutic perspective.
ADA criteria yielded a higher prevalence of pre- 
diabetes in both genders. Furthermore, half of the 
individuals aged 45 years with pre- diabetes according 
to the ADA criteria would never progress to overt 
diabetes, although they would qualify for lifestyle or 
pharmacological intervention according to prevailing 
clinical practice guidelines. The WHO- defined prev-
alences of pre- diabetes were lower, and lifetime risks 
of diabetes were 1.5 times higher compared with ADA 
criteria. The lower cut- off values for the ADA are 
based on results from observations on progression to 
diabetes in Pima Indians and inhabitants of the island 
of Mauritius34 35 and were set to improve the predic-
tion of diabetes risk.12 Altogether, our data show that 
the use of ADA criteria will increase the prevalence 
of pre- diabetes. Although there is a known benefit of 
intensive behavioral lifestyle interventions on weight 
loss and diabetes prevention in subjects with diabetes 
and pre- diabetes7 36), the relative cost- effectiveness 
of these interventions in those with pre- diabetes as 
diagnosed by ADA versus WHO is unknown. Since a 
greater number of individuals at lower lifetime risk of 
disease progression may represent a financial strain to 
the healthcare system, further research is warranted 
to evaluate the cost- effectiveness of screening and 
treating according to both definitions. Importantly, 
since pre- diabetes confers a high risk of cardiovas-
cular morbidity37 mainly explained by clustering of 
cardiometabolic factors associated with hypergly-
cemia,38 extensive lifestyle counseling and cardiovas-
cular risk assessment should not be discarded. An 
individual with pre- diabetes would benefit from inter-
ventions triggered by screening for hypertension and 
dyslipidemia to reduce cardiovascular risk. Although 
it is certainly debatable, we emphasize the impor-
tance of lifestyle medicine in a wider perspective 
than screening and treating for pre- diabetes with low- 
glucose thresholds. Even though we have not studied 
cost- effectiveness in our analyses, a population- based 
approach that aims to change public health behavior 
through general education on diet and lifestyle 
instead of screen- and- treat strategies in high- risk indi-
viduals could be helpful in controlling the diabetes 
epidemic.33 39
Finally, the prevalence of pre- diabetes for both ADA 
and WHO criteria was high at older ages, whereas the 
lifetime risk of diabetes in the elderly with pre- diabetes 
was low due to the limited life expectancy in the higher 
age categories. The current study results implicate that at 
older age, pre- diabetes is less useful as a screening tool 
in order to determine which patients may benefit from 
interventions to prevent diabetes. An observation from a 
12- year follow- up study of older adults with pre- diabetes 
in Sweden showed that the progression rate to diabetes 
was one- third of the progression rate at middle age, and 
common prevention goals promoted reversion to normo-
glycemia.40 Given the low progression rate to diabetes 
and the preventive treatment goals, such as weight 
management, physical activity and blood pressure, one 
could question whether a clinician needs a diagnosis of 
pre- diabetes in elderly to decide to implement preventive 
strategies. This is reflected by a qualitative interview study 
from the UK in which the majority of clinicians tended to 
adjust their management of pre- diabetes to the age and 
perceived risk/benefit to the patient.41 So for the use of 
pre- diabetes to identify high- risk individuals at older age, 
introduction of age- dependent criteria of pre- diabetes 
diagnosis may improve the efficacy to select individuals at 
increased risk of diabetes to justify lifestyle or pharmaco-
logical intervention.
The comprehensive assessment of the diagnosis of 
incident diabetes is a strength of our study, since it was 
done using blood glucose- lowering treatment (identi-
fied from medical records from general practitioners 
and hospitals), repeated study center visits with stan-
dardized blood glucose measurements and linkage with 
pharmacy dispensing records in the study area. Further-
more, we had data from a prospective, population- based 
study with long follow- up and adjusted lifetime risk 
for the competing risk of death in order to correct for 
overestimation.
There are limitations to our study. First, the study popu-
lation was predominantly of European ancestry (>95%). 
Therefore, results may not apply to other ethnic groups. 
Second, the remaining lifetime risk at the age of 45 years 
was calculated because there were no data available for 
individuals younger than 45 years. Nevertheless, the 
cumulative incidence of type 2 diabetes before the age 
of 45 years is low.20 Third, we used data from a study that 
requires active participation through which there is always 
a certain level of healthy volunteer effect. This could lead 
to an underestimation of the absolute risk calculations 
at short- term follow- up. At long- term follow- up, however, 
this underestimation is probably limited.42
In conclusion, we showed that in men and women 
from a community- dwelling population, women with 
pre- diabetes had a significantly higher lifetime risk of 
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diabetes than men. Furthermore, prevalence of pre- 
diabetes doubled when applying ADA compared with 
WHO criteria, and lifetime risk to progress to diabetes 
was substantially lower in women and men with ADA 
pre- diabetes as compared with the WHO pre- diabetes. 
Improvement of pre- diabetes definition would help 
better select individuals at high risk of diabetes. This 
could be done by setting appropriate population- wide 
and sex- specific and age- specific glycemic thresholds. 
Eventually, this would improve the appropriate applica-
tion of both pharmacological and non- pharmacological 
preventive interventions.
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